Anaptysbio, INC 10-K annual reports

AnaptysBio's transition report highlights significant revenue growth from Jemperli sales, driven by GSK's commercialization efforts, alongside strategic updates including a recent business separation.

AnaptysBio amends its 2025 annual report to include details on board composition changes, executive compensation, and related party transactions.

AnaptysBio, a clinical-stage biotechnology company, announced plans to separate into two independent public entities, reporting significant Jemperli sales growth and positive Phase 2b rheumatoid arthritis trial data for rosnilimab.

AnaptysBio achieved key clinical milestones with its lead drug candidate, rosnilimab, and continues to advance its portfolio of immunology therapeutics.

AnaptysBio's 2023 annual report highlights its focus on developing innovative immunology therapeutics, with key updates on its clinical-stage checkpoint agonist programs and strategic collaborations.